William Blair initiated coverage of Natera (NTRA) with an Outperform rating and no price target The firm views Natera as a core, long-term holding for growth-oriented investors. With leading positions across some of the largest markets in diagnostics, the company offers a diversified and growing portfolio of offering, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera: Premium-Valued Leader in MRD Positioned for Long-Term Growth and Margin Expansion
- Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial
- Natera awarded 30% ongoing royalty for MRD-related patents
- Citi opens ‘upside 90-day catalyst watch’ on Natera
- Natera price target lowered to $250 from $260 at Evercore ISI